Since early 2016, cannabis companies have raised almost $2 billion from investors, despite an uncertain legal future complicated by the current anti-legalization position in Congress and the Department of Justice in Washington, as well as the DEA. CBD investment has seen a surge in consumer interest in recent years. Marijuana firms received around $734 million in investment dollars between Jan and April, a major increase from the year prior. Investors seem to believe that the idea of huge potential for growth in legal cannabis related industries, outweighs the risk of adverse legislation, shutting marijuana down once more.
Chronic use and high doses of CBD have repeatedly shown to be easily tolerated by humans and mice, with no neurological, psychiatric, or clinical adverse effects. In one study, 60 mg/kg of CBD was given to mice three times per week for 12 weeks with no adverse effects. Nevertheless, the study did point out that some side effects have been reported with the use of CBD, but these are in vitro or in animal studies. They include alterations of cell viability, lowered fertilization capacity, and inhibition of hepatic drug metabolism and drug transporters. More studies have to be conducted to see if these side effects also occur in humans.